Novavax and Catalent Announce Closing of Strategic Partnership
31 juil. 2019 16h30 HE
|
Novavax, Inc.; Catalent Biologics
GAITHERSBURG, Md., July 31, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and...
Novavax Confirms Accelerated Approval Pathway Available for Licensure of NanoFlu™
27 juin 2019 07h00 HE
|
Novavax, Inc.
Pivotal Phase 3 clinical trial expected to initiate in the fall of 2019Top-line clinical data expected in the first quarter of 2020 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) -- Novavax,...
Novavax and Catalent Biologics Enter Strategic Partnership: Allowing Catalent Biologics to Expand Gene Therapy Footprint with Acquisition of Novavax’ Manufacturing Assets and Capabilities
27 juin 2019 06h59 HE
|
Novavax, Inc.
Manufacturing equipment and related assets to be sold to Catalent’s Paragon Gene Therapy for $18 million in cashOver 100 manufacturing and quality employees to join CatalentParagon Gene Therapy to...
Novavax Provides Updates on the Global Pathways to Licensure for ResVax™
10 juin 2019 06h59 HE
|
Novavax, Inc.
GAITHERSBURG, Md., June 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
Novavax CFO John Trizzino to Discuss Future of Influenza Vaccines on Industry Panel at 2019 BIO International Convention
04 juin 2019 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., June 04, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer,...
Novavax Announces Adjustment of Conversion Rate for its 3.75% Convertible Senior Notes due 2023
10 mai 2019 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., May 10, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced an adjustment to the conversion rate applicable to its existing 3.75% Convertible Senior Notes due...
Novavax Announces Reverse Stock Split of Common Stock
08 mai 2019 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., May 08, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will effect a one-for-twenty reverse stock split of its issued and outstanding common stock....
Novavax Reports First Quarter 2019 Financial Results
02 mai 2019 16h05 HE
|
Novavax, Inc.
Company to Host Conference Call Today at 4:30 p.m. ET GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced its financial results and...
Novavax Announces Presentation of Phase 3 Data from RSV Maternal Immunization Program at 37th Annual Meeting of the European Society for Pediatric Infectious Diseases
01 mai 2019 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., May 01, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Flor M. Muñoz, M.D., M.Sc., Associate Professor of Pediatrics Molecular Virology and...
Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 2, 2019
25 avr. 2019 16h05 HE
|
Novavax, Inc.
GAITHERSBURG, Md., April 25, 2019 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2019 financial and operating results following the close of U.S....